A scholarly position

Why the kidney–obesity intersection deserves dedicated study.

Written for colleagues in nephrology, endocrinology, and obesity medicine. The point is specific: the care of obesity in patients with kidney disease has become coherent and consequential enough to reward focused, structured study and a shared reference — and this resource assembles that study in one place — a structured curriculum, a source-bound study library, and teaching cases. For patients whose defining endpoints are renal, the material is grounded in nephrology, with obesity-medicine competency and close endocrinology / CKM collaboration built in.

What is nephrobesity?

Nephrobesity is shorthand for the two-way relationship between obesity and kidney health. Excess weight can damage the kidneys, and reduced kidney function in turn changes how weight — and the medicines used to treat it — must be managed. This site is an educational focus on that intersection; it is not a new medical specialty.

Obesity can injure the kidney directly — a pattern called obesity-related glomerulopathy — and indirectly, by driving type 2 diabetes and high blood pressure. Working the other way, reduced kidney function reshapes which drugs are chosen and how they are monitored — and, for renally cleared medicines, how they are dosed. Managing one side well means understanding the other.

This obesity–kidney intersection also sits at the core of the cardiovascular–kidney–metabolic (CKM) syndrome: excess adiposity is where the CKM continuum begins, and the kidney is what carries metabolic risk through to the heart. That is why parts of this site engage with CKM — as the wider framework around its obesity–kidney focus, not as a move away from it.

What makes this timely is treatment. New weight-loss medications (GLP-1 and dual-agonist drugs) can meaningfully protect the kidney — but they also raise practical questions about dehydration, dosing, and monitoring that sit exactly at this intersection. These pages explain both the opportunity and the safeguards, clearly and from the evidence.

Below: why this intersection deserves dedicated, structured study.

This is an educational resource and curriculum, not a board specialty or subspecialty, and it does not claim to be one. The claim is practical: care at the intersection of obesity and kidney disease draws on a coherent skill set that spans nephrology, endocrinology, and obesity medicine, and this resource organizes that combined knowledge so clinicians can study it together. For kidney patients, that skill set is grounded in nephrology — because the defining endpoints are renal — and built in collaboration with the other fields. What follows sets out why that intersection rewards dedicated study, in six steps, with its honest limits.

Premise 1 · EpidemiologyTwo intersecting epidemics with a shared trajectory

Obesity is an independent, graded risk factor for incident chronic kidney disease and one of its fastest-growing drivers. It accelerates progression, drives obesity-related glomerulopathy, and complicates both dialysis access and transplant candidacy. The link is increasingly supported as causal by Mendelian-randomization studies of higher BMI and kidney endpoints, alongside large cohort data, and the population carrying both is large and growing.

Crucially, obesity is not a topic sitting beside nephrology; it pervades every one of its subdomains — glomerular disease, hemodialysis, peritoneal dialysis, transplantation, stones, AKI and CKD. A driver that touches every part of nephrology, and changes its endpoints, rewards being studied as a coherent whole.

Premise 2 · MechanismA distinct pathophysiology that treatment can act on

Obesity injures the kidney through mechanisms that are specific and increasingly well characterized: adaptive hyperfiltration and glomerulomegaly, RAAS and sympathetic activation, lipotoxicity and ectopic renal-sinus fat, adipokine signaling, and the metabolic milieu of insulin resistance. Obesity-related glomerulopathy is a nameable lesion with its own histology, distinguishable from diabetic nephropathy and from primary FSGS. A condition with its own mechanism and its own pathology deserves to be engaged in its own right, not treated only as background to other diagnoses.

A lesion with its own mechanism, its own diagnostic problem, and its own therapeutics is one this curriculum treats as a subject in its own right.

Premise 3 · TherapeuticsAn inflection point that draws on both nephrology and obesity medicine

The decisive change is pharmacological. Within a few years, GLP-1 receptor agonists (FLOW) and SGLT2 inhibitors moved from glucose-lowering agents to demonstrated renoprotective therapies, and non-steroidal mineralocorticoid-receptor antagonists (finerenone; FIDELIO-DKD, FIGARO-DKD) added a further cardiorenal mechanism, and dual and triple incretin agonists are advancing behind them. This creates a four-pillar strategy of cardio-renal-metabolic protection that must be sequenced and monitored in the specific setting of a failing nephron.

And this is precisely where existing training divides. The pharmacology of these agents grew out of endocrinology and obesity medicine. The failing nephron — GFR estimation across extremes of muscle mass, dose de-indexing, volume and electrolyte management, the histology, dialysis and transplant — is the domain of nephrology. Using these drugs safely in the failing nephron draws on both nephrology and obesity medicine at once.

Premise 4 · TrainingA skill set that spans two trainings

Nephrology fellowship builds deep expertise in glomerular disease, dialysis, and transplantation; endocrinology and obesity-medicine training bring command of incretin pharmacology and metabolic disease. Caring well for the patient who has both draws on all of it at once — renal-safety surveillance during rapid pharmacological weight loss, dose adjustment in reduced GFR, nutritional reconciliation of fat loss against muscle, and perioperative management of the patient with CKD going to metabolic surgery or onto a transplant list. These are common situations, and this resource brings the relevant competencies together in one place.

Premise 5 · Why nephrology, specificallyFor kidney patients, the natural anchor is the nephron

The therapeutics that made this care urgent grew out of endocrinology and obesity medicine; the endpoints that define the disease are renal — albuminuria, GFR trajectory, progression to kidney failure, the biopsy, the dialysis and transplant continuum — as are the safety questions that make those therapeutics hard and the pathology at issue. So for the patient whose kidneys are failing, the material is organized around renal endpoints and read alongside that pharmacology — nephrology and obesity medicine as co-owners of one problem, each indispensable. Nephrology already studies such intersections closely (onco-nephrology, cardio-nephrology, interventional nephrology, glomerular disease), which makes it a workable home for assembling the material; obesity-medicine competency, formalized through certification such as ABOM, is integral to it, not an add-on.

Premise 6 · Institutional convergenceThe frameworks are already assembling

This is not a case argued from first principles alone; the major societies are already converging on it. The AHA introduced the cardiovascular-kidney-metabolic (CKM) syndrome framework in a 2023 Presidential Advisory, with staging spanning stages 0 through 4, and the first multisociety clinical practice guideline followed in 2026 — authored jointly by the AHA and ACC and co-endorsed by the ADA and the ASN. KDIGO convened a Controversies Conference on obesity and CKD (Prague, 2024), and the ASN issued its first Kidney Health Guidance on the management of obesity in kidney disease (2024). The intellectual architecture is being built in public, by major professional societies. This resource curates that emerging architecture into a single teachable reference.

Shared ground, not a turf claim

Endocrinology and obesity medicine own the therapeutics that made this care urgent; nephrology owns the failing kidney and the endpoints that define it. Both are essential. This resource is explicitly collaborative — it organizes the shared knowledge rather than claiming it for any one field.

Competencies specific to reduced kidney function

In the patient whose kidney function is reduced, several standard rules change. Understanding those changes is the skill set this resource focuses on:

  • Body-composition assessment shifts. BMI and bioimpedance are unreliable with fluid overload or edema; weight change on diuretics or dialysis is not an obesity outcome. Reading body composition through fluid shifts is its own skill.
  • eGFR under GLP-1/GIP. A rising creatinine from muscle loss vs. true AKI vs. a hemodynamic dip (as with SGLT2 inhibitors) — knowing when to hold and when to persevere, and how to place the FLOW data, is nephrological terrain.
  • AKI risk management. The “triple whammy” plus incretin-driven nausea and volume depletion, sick-day rules, and diuretic de-escalation during weight loss — this is Case 01.
  • The protein paradox. Obesity therapy demands high protein to preserve muscle; CKD guidelines demand restriction. Resolving that conflict per patient (stage, proteinuria, sarcopenia risk) belongs to neither field alone.
  • Pharmacokinetics at eGFR <30 and on dialysis. Evidence gaps, off-label territory, dose titration against gastroparesis plus uremia — CKD is a marginal note in the blueprint.
  • Transplant listing. BMI cut-offs as an access barrier, pre-operative weight loss without sarcopenia, GLP-1s under immunosuppression (tacrolimus levels with delayed gastric emptying), post-transplant weight gain on steroids.
  • ORG as its own entity. Obesity-related glomerulopathy, hyperfiltration, obesity-driven proteinuria — pathophysiology, biopsy indication, and course are purely nephrological.
  • Bariatric surgery in CKD. Oxalate nephropathy after Roux-en-Y, nephrolithiasis, and enteric hyperoxaluria — renal complications that reward specific vigilance after malabsorptive procedures.
  • Fluid and electrolyte handling under incretins. Hyponatremia / SIADH signals, natriuresis, RAAS interaction.

In one line: ABOM makes the nephrologist an obesity physician for people with healthy kidneys; this resource addresses what changes when both diseases collide in the same patient — where, today, neither curriculum nor guideline clarity yet exists.

Open questions and the front edge of the evidence

One caveat keeps this rationale honest: parts of the evidence base are still maturing — several renal endpoints for the dual and triple agonists have not yet been reported, and some agents remain investigational; those gaps are flagged where they arise.

Taken together, the six premises make a modest, specific point: a coherent body of knowledge exists here, its therapeutics are consequential and moving quickly, and it is best anchored in nephrology, with endocrinology and obesity-medicine competency built in. That is why this resource exists — to gather the evidence, the competencies, and the teaching in one structured place.

This Nephrobesity resource — its domains, evidence base, and this rationale — is developed and maintained by Amir Naderi, MD.

Read the substance behind the argument.

The ten clinical domains set out the knowledge base in full; the study library binds each claim to a primary source.

The ten clinical domains → Study library →

Evidence anchors

How this resource is developed and maintained

Nephrobesity is written and maintained by a single physician — Dr. Amir S. Naderi (Internal Medicine and Nephrology) — as an independent educational project, not an institutional or society program. Its standards are deliberately explicit:

  • Source-bound. Every substantive claim is tied to a primary source — peer-reviewed literature or society guidance — cited with a PubMed link and an evidence tier that separates established from emerging data.
  • Honest about limits. Surrogate versus hard endpoints, active- versus placebo-controlled comparisons, and investigational or unpublished data are labeled as such; open questions are flagged where they arise.
  • Dated and reviewed. Pages carry a “last updated” date, and time-sensitive claims (trial readouts, regulatory status, guidelines) are re-checked against primary sources on a recurring schedule.
  • Independent. No industry sponsorship; the author reports no relevant financial relationships. Full disclosures and editorial policy are on the About page.
  • Correctable and collaborative. This is a living resource: corrections are welcome, and the intent is to add peer contributors and advisory input over time.

Contributions welcome. This is a living resource that improves through peer input. Clinicians and researchers in nephrology, endocrinology, and obesity medicine are invited to suggest corrections, sources, or additions — write to info@dr-naderi.de.

⚠︎Educational only. This page presents a scholarly rationale for professional discussion; it is not individual medical advice. Nephrobesity is an independent educational resource and curriculum, not a board specialty, subspecialty, or medical society. Citations are evidence anchors; verify current data before formal use.